SAB Biotherapeutics is expected to report a Q3 2026 EPS loss of $0.27 on zero revenue, with the current stock price of $3.82 trading significantly below the average analyst price target of $12.33. The primary focus for investors this quarter remains the clinical progress of SAB-142, a human polyclonal antibody candidate designed to delay the onset of Type 1 Diabetes.
Management is expected to provide updates on patient enrollment for ongoing Phase 1 trials and potential regulatory timelines for subsequent study phases. Additionally, market participants will scrutinize the company's cash burn rate and overall liquidity to ensure the operational runway extends through key 2027 data readouts.